Medical Research
(H80)
IRS Verified
DX Registered
990 on File
CURE SANFILIPPO FOUNDATION
Financial strength (30%)
80/100
Reliability (20%)
50/100
Effectiveness (25%)
81/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Mission Statement
Every parent dreams about their kid’s future and watching it unfold. Sanfilippo Syndrome takes all that away, replacing it with pain and suffering. The child experiences severe dementia and dies in their mid-teens. All before their parents eyes. Cure Sanfilippo Foundation architects and funds cutting-edge research to accelerate discovery of a treatment or cure for Sanfilippo Syndrome so parents can dream of their children’s futures again. Help save children.
Financial Overview — FY 2024
$2.8M
Total Revenue
$1.6M
Total Expenses
$13.7M
Net Assets
5
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
80.1%
Fundraising Efficiency
276.3%
Operating Reserve
104.79x
Liability-to-Asset
1.0%
Revenue Diversification
79.9%
Executive Compensation
$382K
Compared with Peers
FY 2024
Compared with 332 similar organizations
(United States, Medical Research, $1M–$10M in expenses), FY 2024.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
80.1% | 83.0% |
P10P90
|
Below median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
10.6% | 10.7% |
P10P90
|
Above median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
9.3% | 2.0% |
P10P90
|
Bottom quarter |
|
Fundraising efficiency
Fundraising expenses / gross fundraising income
· lower is better
|
276.3% | 97.3% |
P10P90
|
Below median |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
104.8 mo | 12.8 mo |
P10P90
|
Top quarter |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
1.0% | 10.1% |
P10P90
|
Top quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
79.9% | 90.7% |
P10P90
|
Above median |
|
Revenue growth
Year over year revenue growth
|
32.0% | 12.5% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
21.7% | 11.1% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
43.4% | 2.9% |
P10P90
|
Impact
1 program| Outcome / Program | People Served | Cost / Service | # Completed | Duration |
|---|---|---|---|---|
| Clinical Trials funded | 15,000 | $1.00 | 3 | Per Day |
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2024 | $2.8M | $1.6M | $13.7M | 80.1% | 5 |
| 2023 | $2.1M | $1.3M | $11.2M | 80.1% | 4 |
| 2022 | $2.7M | $2.3M | $9.6M | 89.7% | 4 |
| 2021 | $2.2M | $2.6M | N/A | — | 4 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.